Raymond James Financial’s Viridian Therapeutics VRDN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.47M Buy
+71,260
New +$1.52M ﹤0.01% 3751
2026
Q2
– Sell
-293,308
Closed -$5.45M – 5592
2026
Q1
$5.45M Sell
293,308
-10,466
-3% -$311K ﹤0.01% 2512
2025
Q4
$9.42M Sell
303,774
-8,985
-3% -$246K ﹤0.01% 2012
2025
Q3
$6.75M Sell
312,759
-19,330
-6% -$349K ﹤0.01% 2237
2025
Q2
$4.64M Buy
332,089
+13,849
+4% +$188K ﹤0.01% 2430
2025
Q1
$4.29M Buy
318,240
+4,453
+1% +$75.8K ﹤0.01% 2442
2024
Q4
$6.02M Buy
+313,787
New +$6.82M ﹤0.01% 2201

Other funds holding VRDN

Raymond James Financial's VRDN Position: Q3 2026 in Review

Raymond James Financial opened a new position in Viridian Therapeutics (VRDN) in Q3 2026: 71,260 shares worth $1.47M. The stake represents ﹤0.01% of the portfolio and ranks #3751 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in VRDN as recently as Q1 2026.

Raymond James Financial first reported a position in VRDN in Q4 2024 and has held it in 7 quarters since. The position peaked at $9.42M in Q4 2025. 154 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

  • Raymond James Financial held 71,260 shares of Viridian Therapeutics worth $1.47M as of Q3 2026.
  • Viridian Therapeutics was a new Raymond James Financial position in Q3 2026.
  • Viridian Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #3751 holding.
  • Raymond James Financial first reported a position in Viridian Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Viridian Therapeutics position peaked at $9.42M in Q4 2025.
  • 154 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.